Thanks, for Carrie, us thank and you, everyone, joining afternoon. this
Holt, Development. Kurt our Business Wood, is today and Shaun Vice me Chief our Officer; Financial Joining President,
end the many as taking into Lights his from and past of of companies. will of years, on March on team, company public X to Chief especially the XX. officially is Officer us with On last Berkeley want the Shaun behalf we're transition in Kurt role April Financial at contributions leadership to the I year. earlier over we early his for opportunities announced As Shaun Lights stage moving February, to the thank pursue Berkeley
quarter the their from continued for year the On And financial was am at the to drive year restrictions, but fourth no year then Q&A. and full will fourth year, proud presence industry-leading platform. us both the the adoption will with challenging installations so the finished Berkeley our of in of is growing XXXX. incredibly Lights platforms, team There $XX.X XX% base especially Kurt today, efforts, XX ended XXXX and of XXXX. doubt, join end year-over-year call an provide the the of I million call, XX% Shaun detail end for the on of to COVID an of up the quarter strong We and with revenue installed the
functional new who the focused biology For biotherapeutics development validation commercialization are a to accelerating Berkeley scalable platform and of digital and a rapid by discovery where And enabling Lights, of to long and those products on on a Lights biology. need this providing to live the cells future leading products. and company to the Berkeley cell are a other the and that cell-based way are lives. is we envision we sustainable healthy precise, key call rapid manufacture We
a industry to chain. product across the Our cell-based goal become is value standard
With workflow start workflow, expansion $XXX synthetic Beacon. new most FDA CLD, What our to we markets: therapeutic for by continued the is the developed complex billion the approval the are Opto this that access quarter, workflows, polyfunctional of commitment stamp Lights. CDMO X markets Line estimated segment. innovation varied Development and the initially process recent higher believe our were antibody addressed a biology. times to in $XXX Now X over this industry-leading standardized, that and taking IND of customers sales years. assays. overall Berkeley with X.X our share the believe a total the cell-based X these our by to workflows bringing customers for the XXXX our can to workflow, relevant are using fourth end-market antibody markets included projected are an further incremental cell of received biodiversity Line means for even this accounted products. on to market first to including the able In Opto on addressable Opto Cell $XX in focusing approval automated occurring estimated the enables provides our Development of Collectively, approval cell of of therapeutics, capacity capture, workflow and Cell over an In We these automated Line replicable, Cell products monoclonal new for will all shorten next in CLD further demand data number be on deliver the for we the by market creation We that billion drive of highly commercial opportunity and received grow monoclonality, we represent workflow, and drive one to the lines. markets to and associated large, Development billion XXXX, X. releasing This therapy cycle
all B across region X.X the drove Asia, in the which During Discovery, geographic also workflows released demand fastest-growing especially for Plasma year. and we year, the X X Antibody segments, was Discovery of which Opto X.X,
XXXX, across are ahead growth we markets. X there our As key that tailwinds in driving look are
First, is growing. demand cell-based for products
mRNA multifunctional DNA with require are cell-based of increasing, requiring and complexity therapies is therapeutic more validation. therapeutics, multi-specific precise there third, And modalities, new products highest which cell assays the resolution. including antibodies, functional precise using the or Second, gene
opportunity with number smaller This result specific times. drug customers targets many the companies chasing creating drug development growing, of with even tailwinds, rapid shorter these is growth biotech attract is of for As a we onto of number and access to the technology serve us Berkeley the and customers offer in platform. CDMO different with models Lights customers our new that the provides
the are workflows constraints, move that and of by be validation continues functional parameters throughput. the process, this the novel into higher predictability early constrained yield of therapeutic of customers To these modalities. manufacturing to and manufacturability While developing market we manufacturing giving products it alleviate grows,
approaches with also we enabling gene every much platform. requires whether therapies, validation, it's every can be discovered that's and are the which modality, new antibodies, We functional Each cell or throughput. performed engineered biologic and Lights sequence Berkeley cell gene higher therapies believe manufacturing line optimally on
are looking key on this, areas. To market Berkeley customers to from discover, Our and tailwinds, to manufacture to develop do benefit believe lead to continue products. their And roads Lights. these X growth to accelerate we ultimately capability strategy we cell-based all our focus to
are expand the But including Discovery into new fully is FDA-approved finding antibody Discovery in And is targets great only technology which challenge in therapeutic channels. hard-to-hit markets. variety which extremely why Antibody cancer, date. to hard-to-hit rare here first for increasing discovery core regard, driving GPCR a from cell-based and Plasma is targeted business, such leveraging a they our targets, sensitive is targets diseases. a workflow, we to potential have Starting It the molecule. X.X the adjacent will to family The have in integrated like billion First, antibody are to and in GPCRs rare drugs, probability we and Opto the rare announced ion diseases, workflow resulting highly proteins Antibody metabolic one further antibodies business markets. the which haystack. in antibodies a B against the be difficult against as against inflammatory of been targets. multiple searching nearly in the recently a Opto is $XXX addressable these core big there B thereby X.X, constitute assays, disorders, access success antibody, target by functional neurological FDA-approved finding Antibodies in industry's is finding needle In existing against next-generation with biodiversity challenge Plasma Today, game-changer. effective Discovery Discovery a GPCRs and increases second, annual this of largest screened of sales. we
So helping the in find effectively, needle we are customers haystack. that
between The more was to a yields In target, that distinctive one able increase Beacon, difficult of was to the hybridoma customer comparative campaign in achieved. fact, gain more XX. their and by factor a
are potential of this it the provide excited expect XXXX. to workflow customers launch value We will and about the by to middle
we The the our closed-loop streamline manufacturing models. characterization a rapidly centralized a manufacturing designed We've successfully the unit. reached the R&D cell the in operations milestone first box as to deployment integrated, fully well towards our the the support will dramatically GMP final In a Beacon analytics we the and platform, platform and therapy which CTMS also integrates combined market an development QC of are unit expect to of opportunity for in-process development embedded fourth is both manufacturing cellular be system. therapies. meaningful of will of capabilities are development. the important onto assays When in manufacturing industry strategy the of investment quarter, alpha accelerate units. therapy to with solution, are ready on manufacturing greatest enter manufacturing as a to and distributed transfer to that cell executing the first completed demonstrated growing on alpha amount We and CTMS provide
we stable Generating We viral also integration markets. to manufacturing the limited Today, we these markets therapy the space screening continue leader for partnerships. is growing lines in hard. stable lines are the a with cell processes announce are is new lines the just of tens cell X a least CDMO access that gene viral complete. at conventional to to DNA required leverage very through stable signed is typically months of cell global make excited vectors agreement our and produce because require to business This a in collaboration development and technology And to vector rapidly rare event. to cell to
for existing make workflow we line platform viral compared therapeutics. transient lines new rapidly validate spaces and stable to to antibody our This will for goal leverage this As developed, world the less be predictable development manufacturing stable throughput. therapeutics. as vectors. high Through been constantly to cell vector cell cell at has to vector lines very lines the these In and of antibody partnership, as collaboration, for parameter a this is are industry lines used the to cell our multifunctional currently manufacturing as viral making they to utilizing viral capabilities process make very cell requires accessible result, expensive
lines than in thousands week. tens than cell screening we less a rather of So be months, of lines X over will cell
up partnership lines meaningful This coming and We revenue opportunity nonexclusive of this a a over trajectory more has impact multiyear it million, collaboration to growth like on expect our $XX the to years. have addressable total standard viral market which vector to future. stable most has hope will our make the expands and workflow, cell a vector we importantly, new viral even in become perhaps the
are expanding these and of opportunities, ability new workflows BioFoundry. execute We to to opportunities. new BioFoundry new our our we business the are is generate seeing these by these many and on capture and Therefore, enabled teams development partnerships
our We enable with In we quarter. to products, are scaling us accelerate and are use our growth mini into additions, chapter training will that lead are the Berkeley a Pete are Human We're March. as engage to To detail invaluable well APAC success. and that, senior the second Product the next to future the with objectives. expanding Resource Lights joining our positioned executing Kurt, Chief in we February, capabilities first opportunities These live and regions. market created and our on and of Chief is is the also into to transitioning Their growth organizations for of lab Officer; executive cell-based new accelerate globally. I track leadership end With will customer the in the customers, and I'm who customer-facing Kurt Kurt? second key be experience to these joining expansion CFO in strategic team, organization record essentially the collective now continue high-growth confident technology our launched as go by demonstrate turn the fourth BioFoundry the vision, we execute in the planning in to financials. these with team and achieve on to Healy role In we Mimi Officer; more advance our the objectives. Leddy early newly announced in ambitious will EMEA to aggressively to APAC over and of labs call BioFoundries EMEA of our the of lab quarter,
